CovidV2, PascalFrancis, Corpus, bibRecord, 000044

The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice

Identifieur interne : 000044 ( PascalFrancis/Corpus ); précédent : 000043; suivant : 000045

The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice

Auteurs : Masaji Okada ; Yuji Takemoto ; Yoshinobu Okuno ; Satomi Hashimoto ; Shigeto Yoshida ; Yukari Fukunaga ; Takao Tanaka ; Yoko Kita ; Sachiko Kuwayama ; Yumiko Muraki ; Noriko Kanamaru ; Hiroko Takai ; Chika Okada ; Yayoi Sakaguchi ; Izumi Furukawa ; Kyoko Yamada ; Makoto Matsumoto ; Tetsuo Kase ; Daphne E. Demello ; J. S. M. Peiris ; Pei-Jer Chen ; Naoki Yamamoto ; Yoshiyuki Yoshinaka ; Tatsuji Nomura ; Isao Ishida ; Shigeru Morikawa ; Masato Tashiro ; Mitsunori Sakatani

Source :

Vaccine [ 0264-410X ] ; 2005.

RBID : Pascal:06-0198137

Descripteurs français

Pascal (Inist)
- Virus syndrome respiratoire aigu sévère, Souris, Homme, Vaccin génétique, Grave, Lymphocyte T, Cytotoxicité, Immunodéficit mixte, Syndrome respiratoire aigu sévère, Mutation severe combined immunodeficiency (scid).

English descriptors

KwdEn :
- Combined immune deficiency, Cytotoxicity, Genetic vaccine, Human, Mouse, Severe, Severe acute respiratory syndrome, Severe acute respiratory syndrome virus, T-Lymphocyte.

Abstract

We have investigated to develop novel vaccines against SARS CoV using cDNA constructs encoding the structural antigen; spike protein (S), membrane protein (M), envelope protein (E), or nucleocapsid (N) protein, derived from SARS CoV. Mice vaccinated with SARS-N or -M DNA using pcDNA 3.1(+) plasmid vector showed T cell immune responses (CTL induction and proliferation) against N or M protein, respectively. CTL responses were also detected to SARS DNA-transfected type II alveolar epithelial cells (T7 cell clone), which are thought to be initial target cells for SARS virus infection in human. To determine whether these DNA vaccines could induce T cell immune responses in humans as well as in mice, SCID-PBL/hu mice was immunized with these DNA vaccines. As expected, virus-specific CTL responses and T cell proliferation were induced from human T cells. SARS-N and SARS-M DNA vaccines and SCID-PBL/hu mouse model will be important in the development of protective vaccines.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 23`
A06				`@2 17-18`
A08	`01`	`1`	`ENG`	`@1 The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice`
A09	`01`	`1`	`ENG`	`@1 Vaccines and immunisation. Based on the fourth world congress on vaccines and immunisation, Tsukuba Science City/Tokyo, Japan, 30 september-3 october 2004`
A11	`01`	`1`		`@1 OKADA (Masaji)`
A11	`02`	`1`		`@1 TAKEMOTO (Yuji)`
A11	`03`	`1`		`@1 OKUNO (Yoshinobu)`
A11	`04`	`1`		`@1 HASHIMOTO (Satomi)`
A11	`05`	`1`		`@1 YOSHIDA (Shigeto)`
A11	`06`	`1`		`@1 FUKUNAGA (Yukari)`
A11	`07`	`1`		`@1 TANAKA (Takao)`
A11	`08`	`1`		`@1 KITA (Yoko)`
A11	`09`	`1`		`@1 KUWAYAMA (Sachiko)`
A11	`10`	`1`		`@1 MURAKI (Yumiko)`
A11	`11`	`1`		`@1 KANAMARU (Noriko)`
A11	`12`	`1`		`@1 TAKAI (Hiroko)`
A11	`13`	`1`		`@1 OKADA (Chika)`
A11	`14`	`1`		`@1 SAKAGUCHI (Yayoi)`
A11	`15`	`1`		`@1 FURUKAWA (Izumi)`
A11	`16`	`1`		`@1 YAMADA (Kyoko)`
A11	`17`	`1`		`@1 MATSUMOTO (Makoto)`
A11	`18`	`1`		`@1 KASE (Tetsuo)`
A11	`19`	`1`		`@1 DEMELLO (Daphne E.)`
A11	`20`	`1`		`@1 PEIRIS (J. S. M.)`
A11	`21`	`1`		`@1 CHEN (Pei-Jer)`
A11	`22`	`1`		`@1 YAMAMOTO (Naoki)`
A11	`23`	`1`		`@1 YOSHINAKA (Yoshiyuki)`
A11	`24`	`1`		`@1 NOMURA (Tatsuji)`
A11	`25`	`1`		`@1 ISHIDA (Isao)`
A11	`26`	`1`		`@1 MORIKAWA (Shigeru)`
A11	`27`	`1`		`@1 TASHIRO (Masato)`
A11	`28`	`1`		`@1 SAKATANI (Mitsunori)`
A12	`01`	`1`		`@1 KURSTAK (Edouard) @9 ed.`
A14	`01`			`@1 Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone @2 Sakai, Osaka 591-8555 @3 JPN @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut. @Z 9 aut. @Z 10 aut. @Z 11 aut. @Z 12 aut. @Z 13 aut. @Z 14 aut. @Z 15 aut. @Z 16 aut. @Z 28 aut.`
A14	`02`			`@1 Department of Infectious Diseases, Osaka Prefectural Institute of Public Health @2 3-69 Nakamichi 1-chome Higashinari-ku, Osaka 537-0025 @3 JPN @Z 3 aut. @Z 18 aut.`
A14	`03`			`@1 Department of Infection and Immunity, Jichi Medical School, 3311-1 Yakushiji @2 Minamikawachi-machi, Tochigi 329-0498 @3 JPN @Z 5 aut.`
A14	`04`			`@1 Microbiological Research Institute, Otsuka Pharmaceutical Co., Ltd., 463-10, Kagasuno @2 Kawauchi-cho, Tokushima 771-019 @3 JPN @Z 17 aut.`
A14	`05`			`@1 Department of Pathology Cardinal Glennon Children's Hospital, St. Louis University Health Science Center, 1465 South Grand Blvd @2 St. Louis, MO 63104 @3 USA @Z 19 aut.`
A14	`06`			`@1 Department of Microbiology, The University of Hong Kong, Pokfulam Road @3 HKG @Z 20 aut.`
A14	`07`			`@1 Hepatitis Research Center, National Taiwan University College of Medicine, Room 328, 3F, No. 1, Sec. 1, Ren-ai Rd @2 Jhongjheng District 100, Taipei @3 TWN @Z 21 aut.`
A14	`08`			`@1 Tokyo Medical and Dental University, 1-5-45 Yushima @2 Bunkyo-ku, Tokyo 113-8549 @3 JPN @Z 22 aut. @Z 23 aut.`
A14	`09`			`@1 Central Institute for Experimental Animals, 1430 Nogawa, Miyamae @2 Kawasaki, Kanagawa 216-0001 @3 JPN @Z 24 aut.`
A14	`10`			`@1 Pharmaceutical Division, Kirin Brewery Co., 6-26-1 Jingumae @2 Shibuya, Tokyo 150-8011 @3 JPN @Z 25 aut.`
A14	`11`			`@1 National Institute of Infectious Diseases, 1-23-1 Toyama @2 Shinjuku-ku, Tokyo 162-8640 @3 JPN @Z 26 aut. @Z 27 aut.`
A15	`01`			`@1 Infections Control World Organization, Faculty of Medicine, University of Montreal @2 Montreal, Que., H3C 3J7 @3 CAN @Z 1 aut.`
A18	`01`	`1`		`@1 Infections Control World Organization (ICWO) @3 CAN @9 patr.`
A20				`@1 2269-2272`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000133094560450`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 9 ref.`
A47	`01`	`1`		`@0 06-0198137`
A60				`@1 P @2 C`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 We have investigated to develop novel vaccines against SARS CoV using cDNA constructs encoding the structural antigen; spike protein (S), membrane protein (M), envelope protein (E), or nucleocapsid (N) protein, derived from SARS CoV. Mice vaccinated with SARS-N or -M DNA using pcDNA 3.1(+) plasmid vector showed T cell immune responses (CTL induction and proliferation) against N or M protein, respectively. CTL responses were also detected to SARS DNA-transfected type II alveolar epithelial cells (T7 cell clone), which are thought to be initial target cells for SARS virus infection in human. To determine whether these DNA vaccines could induce T cell immune responses in humans as well as in mice, SCID-PBL/hu mice was immunized with these DNA vaccines. As expected, virus-specific CTL responses and T cell proliferation were induced from human T cells. SARS-N and SARS-M DNA vaccines and SCID-PBL/hu mouse model will be important in the development of protective vaccines.
C02	`01`	`X`		`@0 002A05F04`
C03	`01`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Souris @5 02`
C03	`02`	`X`	`ENG`	`@0 Mouse @5 02`
C03	`02`	`X`	`SPA`	`@0 Ratón @5 02`
C03	`03`	`X`	`FRE`	`@0 Homme @5 03`
C03	`03`	`X`	`ENG`	`@0 Human @5 03`
C03	`03`	`X`	`SPA`	`@0 Hombre @5 03`
C03	`04`	`X`	`FRE`	`@0 Vaccin génétique @5 05`
C03	`04`	`X`	`ENG`	`@0 Genetic vaccine @5 05`
C03	`04`	`X`	`SPA`	`@0 Vaccina genética @5 05`
C03	`05`	`X`	`FRE`	`@0 Grave @5 06`
C03	`05`	`X`	`ENG`	`@0 Severe @5 06`
C03	`05`	`X`	`SPA`	`@0 Grave @5 06`
C03	`06`	`X`	`FRE`	`@0 Lymphocyte T @5 07`
C03	`06`	`X`	`ENG`	`@0 T-Lymphocyte @5 07 @6 «T»-Lymphocyte`
C03	`06`	`X`	`SPA`	`@0 Linfocito T @5 07`
C03	`07`	`X`	`FRE`	`@0 Cytotoxicité @5 08`
C03	`07`	`X`	`ENG`	`@0 Cytotoxicity @5 08`
C03	`07`	`X`	`SPA`	`@0 Citotoxicidad @5 08`
C03	`08`	`X`	`FRE`	`@0 Immunodéficit mixte @2 NM @5 14`
C03	`08`	`X`	`ENG`	`@0 Combined immune deficiency @2 NM @5 14`
C03	`08`	`X`	`SPA`	`@0 Inmunodeficiencia mixta @2 NM @5 14`
C03	`09`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 15`
C03	`09`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 15`
C03	`09`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 15`
C03	`10`	`X`	`FRE`	`@0 Mutation severe combined immunodeficiency (scid) @4 INC @5 79`
C07	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`05`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`05`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`06`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`06`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`06`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`07`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`07`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`07`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`08`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 13`
C07	`08`	`X`	`ENG`	`@0 Respiratory disease @5 13`
C07	`08`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 13`
C07	`09`	`X`	`FRE`	`@0 Virose`
C07	`09`	`X`	`ENG`	`@0 Viral disease`
C07	`09`	`X`	`SPA`	`@0 Virosis`
C07	`10`	`X`	`FRE`	`@0 Infection`
C07	`10`	`X`	`ENG`	`@0 Infection`
C07	`10`	`X`	`SPA`	`@0 Infección`
C07	`11`	`X`	`FRE`	`@0 Poumon pathologie @5 16`
C07	`11`	`X`	`ENG`	`@0 Lung disease @5 16`
C07	`11`	`X`	`SPA`	`@0 Pulmón patología @5 16`
N21				`@1 121`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

A30	`01`	`1`	`ENG`	`@1 World Congress on Vaccines and Immunisation @2 4 @3 Tokyo JPN @4 2004-09-30`

Format Inist (serveur)

NO :	PASCAL 06-0198137 INIST
ET :	The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice
AU :	OKADA (Masaji); TAKEMOTO (Yuji); OKUNO (Yoshinobu); HASHIMOTO (Satomi); YOSHIDA (Shigeto); FUKUNAGA (Yukari); TANAKA (Takao); KITA (Yoko); KUWAYAMA (Sachiko); MURAKI (Yumiko); KANAMARU (Noriko); TAKAI (Hiroko); OKADA (Chika); SAKAGUCHI (Yayoi); FURUKAWA (Izumi); YAMADA (Kyoko); MATSUMOTO (Makoto); KASE (Tetsuo); DEMELLO (Daphne E.); PEIRIS (J. S. M.); CHEN (Pei-Jer); YAMAMOTO (Naoki); YOSHINAKA (Yoshiyuki); NOMURA (Tatsuji); ISHIDA (Isao); MORIKAWA (Shigeru); TASHIRO (Masato); SAKATANI (Mitsunori); KURSTAK (Edouard)
AF :	Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone/Sakai, Osaka 591-8555/Japon (1 aut., 2 aut., 4 aut., 6 aut., 7 aut., 8 aut., 9 aut., 10 aut., 11 aut., 12 aut., 13 aut., 14 aut., 15 aut., 16 aut., 28 aut.); Department of Infectious Diseases, Osaka Prefectural Institute of Public Health/3-69 Nakamichi 1-chome Higashinari-ku, Osaka 537-0025/Japon (3 aut., 18 aut.); Department of Infection and Immunity, Jichi Medical School, 3311-1 Yakushiji/Minamikawachi-machi, Tochigi 329-0498/Japon (5 aut.); Microbiological Research Institute, Otsuka Pharmaceutical Co., Ltd., 463-10, Kagasuno/Kawauchi-cho, Tokushima 771-019/Japon (17 aut.); Department of Pathology Cardinal Glennon Children's Hospital, St. Louis University Health Science Center, 1465 South Grand Blvd/St. Louis, MO 63104/Etats-Unis (19 aut.); Department of Microbiology, The University of Hong Kong, Pokfulam Road/Hong-Kong (20 aut.); Hepatitis Research Center, National Taiwan University College of Medicine, Room 328, 3F, No. 1, Sec. 1, Ren-ai Rd/Jhongjheng District 100, Taipei/Taïwan (21 aut.); Tokyo Medical and Dental University, 1-5-45 Yushima/Bunkyo-ku, Tokyo 113-8549/Japon (22 aut., 23 aut.); Central Institute for Experimental Animals, 1430 Nogawa, Miyamae/Kawasaki, Kanagawa 216-0001/Japon (24 aut.); Pharmaceutical Division, Kirin Brewery Co., 6-26-1 Jingumae/Shibuya, Tokyo 150-8011/Japon (25 aut.); National Institute of Infectious Diseases, 1-23-1 Toyama/Shinjuku-ku, Tokyo 162-8640/Japon (26 aut., 27 aut.); Infections Control World Organization, Faculty of Medicine, University of Montreal/Montreal, Que., H3C 3J7/Canada (1 aut.)
DT :	Publication en série; Congrès; Niveau analytique
SO :	Vaccine; ISSN 0264-410X; Coden VACCDE; Royaume-Uni; Da. 2005; Vol. 23; No. 17-18; Pp. 2269-2272; Bibl. 9 ref.
LA :	Anglais
EA :	We have investigated to develop novel vaccines against SARS CoV using cDNA constructs encoding the structural antigen; spike protein (S), membrane protein (M), envelope protein (E), or nucleocapsid (N) protein, derived from SARS CoV. Mice vaccinated with SARS-N or -M DNA using pcDNA 3.1(+) plasmid vector showed T cell immune responses (CTL induction and proliferation) against N or M protein, respectively. CTL responses were also detected to SARS DNA-transfected type II alveolar epithelial cells (T7 cell clone), which are thought to be initial target cells for SARS virus infection in human. To determine whether these DNA vaccines could induce T cell immune responses in humans as well as in mice, SCID-PBL/hu mice was immunized with these DNA vaccines. As expected, virus-specific CTL responses and T cell proliferation were induced from human T cells. SARS-N and SARS-M DNA vaccines and SCID-PBL/hu mouse model will be important in the development of protective vaccines.
CC :	002A05F04
FD :	Virus syndrome respiratoire aigu sévère; Souris; Homme; Vaccin génétique; Grave; Lymphocyte T; Cytotoxicité; Immunodéficit mixte; Syndrome respiratoire aigu sévère; Mutation severe combined immunodeficiency (scid)
FG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Rodentia; Mammalia; Vertebrata; Appareil respiratoire pathologie; Virose; Infection; Poumon pathologie
ED :	Severe acute respiratory syndrome virus; Mouse; Human; Genetic vaccine; Severe; T-Lymphocyte; Cytotoxicity; Combined immune deficiency; Severe acute respiratory syndrome
EG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Rodentia; Mammalia; Vertebrata; Respiratory disease; Viral disease; Infection; Lung disease
SD :	Severe acute respiratory syndrome virus; Ratón; Hombre; Vaccina genética; Grave; Linfocito T; Citotoxicidad; Inmunodeficiencia mixta; Síndrome respiratorio agudo severo
LO :	INIST-20289.354000133094560450
ID :	06-0198137

Links to Exploration step

Pascal:06-0198137

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice</title>
<author><name sortKey="Okada, Masaji" sort="Okada, Masaji" uniqKey="Okada M" first="Masaji" last="Okada">Masaji Okada</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Takemoto, Yuji" sort="Takemoto, Yuji" uniqKey="Takemoto Y" first="Yuji" last="Takemoto">Yuji Takemoto</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Okuno, Yoshinobu" sort="Okuno, Yoshinobu" uniqKey="Okuno Y" first="Yoshinobu" last="Okuno">Yoshinobu Okuno</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Infectious Diseases, Osaka Prefectural Institute of Public Health</s1>
<s2>3-69 Nakamichi 1-chome Higashinari-ku, Osaka 537-0025</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hashimoto, Satomi" sort="Hashimoto, Satomi" uniqKey="Hashimoto S" first="Satomi" last="Hashimoto">Satomi Hashimoto</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yoshida, Shigeto" sort="Yoshida, Shigeto" uniqKey="Yoshida S" first="Shigeto" last="Yoshida">Shigeto Yoshida</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Infection and Immunity, Jichi Medical School, 3311-1 Yakushiji</s1>
<s2>Minamikawachi-machi, Tochigi 329-0498</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fukunaga, Yukari" sort="Fukunaga, Yukari" uniqKey="Fukunaga Y" first="Yukari" last="Fukunaga">Yukari Fukunaga</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tanaka, Takao" sort="Tanaka, Takao" uniqKey="Tanaka T" first="Takao" last="Tanaka">Takao Tanaka</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kita, Yoko" sort="Kita, Yoko" uniqKey="Kita Y" first="Yoko" last="Kita">Yoko Kita</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kuwayama, Sachiko" sort="Kuwayama, Sachiko" uniqKey="Kuwayama S" first="Sachiko" last="Kuwayama">Sachiko Kuwayama</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Muraki, Yumiko" sort="Muraki, Yumiko" uniqKey="Muraki Y" first="Yumiko" last="Muraki">Yumiko Muraki</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kanamaru, Noriko" sort="Kanamaru, Noriko" uniqKey="Kanamaru N" first="Noriko" last="Kanamaru">Noriko Kanamaru</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Takai, Hiroko" sort="Takai, Hiroko" uniqKey="Takai H" first="Hiroko" last="Takai">Hiroko Takai</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Okada, Chika" sort="Okada, Chika" uniqKey="Okada C" first="Chika" last="Okada">Chika Okada</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sakaguchi, Yayoi" sort="Sakaguchi, Yayoi" uniqKey="Sakaguchi Y" first="Yayoi" last="Sakaguchi">Yayoi Sakaguchi</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Furukawa, Izumi" sort="Furukawa, Izumi" uniqKey="Furukawa I" first="Izumi" last="Furukawa">Izumi Furukawa</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yamada, Kyoko" sort="Yamada, Kyoko" uniqKey="Yamada K" first="Kyoko" last="Yamada">Kyoko Yamada</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Matsumoto, Makoto" sort="Matsumoto, Makoto" uniqKey="Matsumoto M" first="Makoto" last="Matsumoto">Makoto Matsumoto</name>
<affiliation><inist:fA14 i1="04"><s1>Microbiological Research Institute, Otsuka Pharmaceutical Co., Ltd., 463-10, Kagasuno</s1>
<s2>Kawauchi-cho, Tokushima 771-019</s2>
<s3>JPN</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kase, Tetsuo" sort="Kase, Tetsuo" uniqKey="Kase T" first="Tetsuo" last="Kase">Tetsuo Kase</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Infectious Diseases, Osaka Prefectural Institute of Public Health</s1>
<s2>3-69 Nakamichi 1-chome Higashinari-ku, Osaka 537-0025</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Demello, Daphne E" sort="Demello, Daphne E" uniqKey="Demello D" first="Daphne E." last="Demello">Daphne E. Demello</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Pathology Cardinal Glennon Children's Hospital, St. Louis University Health Science Center, 1465 South Grand Blvd</s1>
<s2>St. Louis, MO 63104</s2>
<s3>USA</s3>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peiris, J S M" sort="Peiris, J S M" uniqKey="Peiris J" first="J. S. M." last="Peiris">J. S. M. Peiris</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Microbiology, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chen, Pei Jer" sort="Chen, Pei Jer" uniqKey="Chen P" first="Pei-Jer" last="Chen">Pei-Jer Chen</name>
<affiliation><inist:fA14 i1="07"><s1>Hepatitis Research Center, National Taiwan University College of Medicine, Room 328, 3F, No. 1, Sec. 1, Ren-ai Rd</s1>
<s2>Jhongjheng District 100, Taipei</s2>
<s3>TWN</s3>
<sZ>21 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name>
<affiliation><inist:fA14 i1="08"><s1>Tokyo Medical and Dental University, 1-5-45 Yushima</s1>
<s2>Bunkyo-ku, Tokyo 113-8549</s2>
<s3>JPN</s3>
<sZ>22 aut.</sZ>
<sZ>23 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yoshinaka, Yoshiyuki" sort="Yoshinaka, Yoshiyuki" uniqKey="Yoshinaka Y" first="Yoshiyuki" last="Yoshinaka">Yoshiyuki Yoshinaka</name>
<affiliation><inist:fA14 i1="08"><s1>Tokyo Medical and Dental University, 1-5-45 Yushima</s1>
<s2>Bunkyo-ku, Tokyo 113-8549</s2>
<s3>JPN</s3>
<sZ>22 aut.</sZ>
<sZ>23 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nomura, Tatsuji" sort="Nomura, Tatsuji" uniqKey="Nomura T" first="Tatsuji" last="Nomura">Tatsuji Nomura</name>
<affiliation><inist:fA14 i1="09"><s1>Central Institute for Experimental Animals, 1430 Nogawa, Miyamae</s1>
<s2>Kawasaki, Kanagawa 216-0001</s2>
<s3>JPN</s3>
<sZ>24 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ishida, Isao" sort="Ishida, Isao" uniqKey="Ishida I" first="Isao" last="Ishida">Isao Ishida</name>
<affiliation><inist:fA14 i1="10"><s1>Pharmaceutical Division, Kirin Brewery Co., 6-26-1 Jingumae</s1>
<s2>Shibuya, Tokyo 150-8011</s2>
<s3>JPN</s3>
<sZ>25 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name>
<affiliation><inist:fA14 i1="11"><s1>National Institute of Infectious Diseases, 1-23-1 Toyama</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>26 aut.</sZ>
<sZ>27 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tashiro, Masato" sort="Tashiro, Masato" uniqKey="Tashiro M" first="Masato" last="Tashiro">Masato Tashiro</name>
<affiliation><inist:fA14 i1="11"><s1>National Institute of Infectious Diseases, 1-23-1 Toyama</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>26 aut.</sZ>
<sZ>27 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sakatani, Mitsunori" sort="Sakatani, Mitsunori" uniqKey="Sakatani M" first="Mitsunori" last="Sakatani">Mitsunori Sakatani</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0198137</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 06-0198137 INIST</idno>
<idno type="RBID">Pascal:06-0198137</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000044</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice</title>
<author><name sortKey="Okada, Masaji" sort="Okada, Masaji" uniqKey="Okada M" first="Masaji" last="Okada">Masaji Okada</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Takemoto, Yuji" sort="Takemoto, Yuji" uniqKey="Takemoto Y" first="Yuji" last="Takemoto">Yuji Takemoto</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Okuno, Yoshinobu" sort="Okuno, Yoshinobu" uniqKey="Okuno Y" first="Yoshinobu" last="Okuno">Yoshinobu Okuno</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Infectious Diseases, Osaka Prefectural Institute of Public Health</s1>
<s2>3-69 Nakamichi 1-chome Higashinari-ku, Osaka 537-0025</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hashimoto, Satomi" sort="Hashimoto, Satomi" uniqKey="Hashimoto S" first="Satomi" last="Hashimoto">Satomi Hashimoto</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yoshida, Shigeto" sort="Yoshida, Shigeto" uniqKey="Yoshida S" first="Shigeto" last="Yoshida">Shigeto Yoshida</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Infection and Immunity, Jichi Medical School, 3311-1 Yakushiji</s1>
<s2>Minamikawachi-machi, Tochigi 329-0498</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fukunaga, Yukari" sort="Fukunaga, Yukari" uniqKey="Fukunaga Y" first="Yukari" last="Fukunaga">Yukari Fukunaga</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tanaka, Takao" sort="Tanaka, Takao" uniqKey="Tanaka T" first="Takao" last="Tanaka">Takao Tanaka</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kita, Yoko" sort="Kita, Yoko" uniqKey="Kita Y" first="Yoko" last="Kita">Yoko Kita</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kuwayama, Sachiko" sort="Kuwayama, Sachiko" uniqKey="Kuwayama S" first="Sachiko" last="Kuwayama">Sachiko Kuwayama</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Muraki, Yumiko" sort="Muraki, Yumiko" uniqKey="Muraki Y" first="Yumiko" last="Muraki">Yumiko Muraki</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kanamaru, Noriko" sort="Kanamaru, Noriko" uniqKey="Kanamaru N" first="Noriko" last="Kanamaru">Noriko Kanamaru</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Takai, Hiroko" sort="Takai, Hiroko" uniqKey="Takai H" first="Hiroko" last="Takai">Hiroko Takai</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Okada, Chika" sort="Okada, Chika" uniqKey="Okada C" first="Chika" last="Okada">Chika Okada</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sakaguchi, Yayoi" sort="Sakaguchi, Yayoi" uniqKey="Sakaguchi Y" first="Yayoi" last="Sakaguchi">Yayoi Sakaguchi</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Furukawa, Izumi" sort="Furukawa, Izumi" uniqKey="Furukawa I" first="Izumi" last="Furukawa">Izumi Furukawa</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yamada, Kyoko" sort="Yamada, Kyoko" uniqKey="Yamada K" first="Kyoko" last="Yamada">Kyoko Yamada</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Matsumoto, Makoto" sort="Matsumoto, Makoto" uniqKey="Matsumoto M" first="Makoto" last="Matsumoto">Makoto Matsumoto</name>
<affiliation><inist:fA14 i1="04"><s1>Microbiological Research Institute, Otsuka Pharmaceutical Co., Ltd., 463-10, Kagasuno</s1>
<s2>Kawauchi-cho, Tokushima 771-019</s2>
<s3>JPN</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kase, Tetsuo" sort="Kase, Tetsuo" uniqKey="Kase T" first="Tetsuo" last="Kase">Tetsuo Kase</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Infectious Diseases, Osaka Prefectural Institute of Public Health</s1>
<s2>3-69 Nakamichi 1-chome Higashinari-ku, Osaka 537-0025</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Demello, Daphne E" sort="Demello, Daphne E" uniqKey="Demello D" first="Daphne E." last="Demello">Daphne E. Demello</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Pathology Cardinal Glennon Children's Hospital, St. Louis University Health Science Center, 1465 South Grand Blvd</s1>
<s2>St. Louis, MO 63104</s2>
<s3>USA</s3>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peiris, J S M" sort="Peiris, J S M" uniqKey="Peiris J" first="J. S. M." last="Peiris">J. S. M. Peiris</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Microbiology, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chen, Pei Jer" sort="Chen, Pei Jer" uniqKey="Chen P" first="Pei-Jer" last="Chen">Pei-Jer Chen</name>
<affiliation><inist:fA14 i1="07"><s1>Hepatitis Research Center, National Taiwan University College of Medicine, Room 328, 3F, No. 1, Sec. 1, Ren-ai Rd</s1>
<s2>Jhongjheng District 100, Taipei</s2>
<s3>TWN</s3>
<sZ>21 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name>
<affiliation><inist:fA14 i1="08"><s1>Tokyo Medical and Dental University, 1-5-45 Yushima</s1>
<s2>Bunkyo-ku, Tokyo 113-8549</s2>
<s3>JPN</s3>
<sZ>22 aut.</sZ>
<sZ>23 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yoshinaka, Yoshiyuki" sort="Yoshinaka, Yoshiyuki" uniqKey="Yoshinaka Y" first="Yoshiyuki" last="Yoshinaka">Yoshiyuki Yoshinaka</name>
<affiliation><inist:fA14 i1="08"><s1>Tokyo Medical and Dental University, 1-5-45 Yushima</s1>
<s2>Bunkyo-ku, Tokyo 113-8549</s2>
<s3>JPN</s3>
<sZ>22 aut.</sZ>
<sZ>23 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nomura, Tatsuji" sort="Nomura, Tatsuji" uniqKey="Nomura T" first="Tatsuji" last="Nomura">Tatsuji Nomura</name>
<affiliation><inist:fA14 i1="09"><s1>Central Institute for Experimental Animals, 1430 Nogawa, Miyamae</s1>
<s2>Kawasaki, Kanagawa 216-0001</s2>
<s3>JPN</s3>
<sZ>24 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ishida, Isao" sort="Ishida, Isao" uniqKey="Ishida I" first="Isao" last="Ishida">Isao Ishida</name>
<affiliation><inist:fA14 i1="10"><s1>Pharmaceutical Division, Kirin Brewery Co., 6-26-1 Jingumae</s1>
<s2>Shibuya, Tokyo 150-8011</s2>
<s3>JPN</s3>
<sZ>25 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name>
<affiliation><inist:fA14 i1="11"><s1>National Institute of Infectious Diseases, 1-23-1 Toyama</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>26 aut.</sZ>
<sZ>27 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tashiro, Masato" sort="Tashiro, Masato" uniqKey="Tashiro M" first="Masato" last="Tashiro">Masato Tashiro</name>
<affiliation><inist:fA14 i1="11"><s1>National Institute of Infectious Diseases, 1-23-1 Toyama</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>26 aut.</sZ>
<sZ>27 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sakatani, Mitsunori" sort="Sakatani, Mitsunori" uniqKey="Sakatani M" first="Mitsunori" last="Sakatani">Mitsunori Sakatani</name>
<affiliation><inist:fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Combined immune deficiency</term>
<term>Cytotoxicity</term>
<term>Genetic vaccine</term>
<term>Human</term>
<term>Mouse</term>
<term>Severe</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
<term>T-Lymphocyte</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus syndrome respiratoire aigu sévère</term>
<term>Souris</term>
<term>Homme</term>
<term>Vaccin génétique</term>
<term>Grave</term>
<term>Lymphocyte T</term>
<term>Cytotoxicité</term>
<term>Immunodéficit mixte</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Mutation severe combined immunodeficiency (scid)</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We have investigated to develop novel vaccines against SARS CoV using cDNA constructs encoding the structural antigen; spike protein (S), membrane protein (M), envelope protein (E), or nucleocapsid (N) protein, derived from SARS CoV. Mice vaccinated with SARS-N or -M DNA using pcDNA 3.1(+) plasmid vector showed T cell immune responses (CTL induction and proliferation) against N or M protein, respectively. CTL responses were also detected to SARS DNA-transfected type II alveolar epithelial cells (T7 cell clone), which are thought to be initial target cells for SARS virus infection in human. To determine whether these DNA vaccines could induce T cell immune responses in humans as well as in mice, SCID-PBL/hu mice was immunized with these DNA vaccines. As expected, virus-specific CTL responses and T cell proliferation were induced from human T cells. SARS-N and SARS-M DNA vaccines and SCID-PBL/hu mouse model will be important in the development of protective vaccines.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>17-18</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Vaccines and immunisation. Based on the fourth world congress on vaccines and immunisation, Tsukuba Science City/Tokyo, Japan, 30 september-3 october 2004</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>OKADA (Masaji)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TAKEMOTO (Yuji)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>OKUNO (Yoshinobu)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HASHIMOTO (Satomi)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>YOSHIDA (Shigeto)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>FUKUNAGA (Yukari)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>TANAKA (Takao)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>KITA (Yoko)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>KUWAYAMA (Sachiko)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MURAKI (Yumiko)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>KANAMARU (Noriko)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>TAKAI (Hiroko)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>OKADA (Chika)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>SAKAGUCHI (Yayoi)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>FURUKAWA (Izumi)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>YAMADA (Kyoko)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>MATSUMOTO (Makoto)</s1>
</fA11>
<fA11 i1="18" i2="1"><s1>KASE (Tetsuo)</s1>
</fA11>
<fA11 i1="19" i2="1"><s1>DEMELLO (Daphne E.)</s1>
</fA11>
<fA11 i1="20" i2="1"><s1>PEIRIS (J. S. M.)</s1>
</fA11>
<fA11 i1="21" i2="1"><s1>CHEN (Pei-Jer)</s1>
</fA11>
<fA11 i1="22" i2="1"><s1>YAMAMOTO (Naoki)</s1>
</fA11>
<fA11 i1="23" i2="1"><s1>YOSHINAKA (Yoshiyuki)</s1>
</fA11>
<fA11 i1="24" i2="1"><s1>NOMURA (Tatsuji)</s1>
</fA11>
<fA11 i1="25" i2="1"><s1>ISHIDA (Isao)</s1>
</fA11>
<fA11 i1="26" i2="1"><s1>MORIKAWA (Shigeru)</s1>
</fA11>
<fA11 i1="27" i2="1"><s1>TASHIRO (Masato)</s1>
</fA11>
<fA11 i1="28" i2="1"><s1>SAKATANI (Mitsunori)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>KURSTAK (Edouard)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone</s1>
<s2>Sakai, Osaka 591-8555</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>28 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Infectious Diseases, Osaka Prefectural Institute of Public Health</s1>
<s2>3-69 Nakamichi 1-chome Higashinari-ku, Osaka 537-0025</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
<sZ>18 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Infection and Immunity, Jichi Medical School, 3311-1 Yakushiji</s1>
<s2>Minamikawachi-machi, Tochigi 329-0498</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Microbiological Research Institute, Otsuka Pharmaceutical Co., Ltd., 463-10, Kagasuno</s1>
<s2>Kawauchi-cho, Tokushima 771-019</s2>
<s3>JPN</s3>
<sZ>17 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Pathology Cardinal Glennon Children's Hospital, St. Louis University Health Science Center, 1465 South Grand Blvd</s1>
<s2>St. Louis, MO 63104</s2>
<s3>USA</s3>
<sZ>19 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Microbiology, The University of Hong Kong, Pokfulam Road</s1>
<s3>HKG</s3>
<sZ>20 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Hepatitis Research Center, National Taiwan University College of Medicine, Room 328, 3F, No. 1, Sec. 1, Ren-ai Rd</s1>
<s2>Jhongjheng District 100, Taipei</s2>
<s3>TWN</s3>
<sZ>21 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Tokyo Medical and Dental University, 1-5-45 Yushima</s1>
<s2>Bunkyo-ku, Tokyo 113-8549</s2>
<s3>JPN</s3>
<sZ>22 aut.</sZ>
<sZ>23 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Central Institute for Experimental Animals, 1430 Nogawa, Miyamae</s1>
<s2>Kawasaki, Kanagawa 216-0001</s2>
<s3>JPN</s3>
<sZ>24 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Pharmaceutical Division, Kirin Brewery Co., 6-26-1 Jingumae</s1>
<s2>Shibuya, Tokyo 150-8011</s2>
<s3>JPN</s3>
<sZ>25 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>National Institute of Infectious Diseases, 1-23-1 Toyama</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>26 aut.</sZ>
<sZ>27 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Infections Control World Organization, Faculty of Medicine, University of Montreal</s1>
<s2>Montreal, Que., H3C 3J7</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA18 i1="01" i2="1"><s1>Infections Control World Organization (ICWO)</s1>
<s3>CAN</s3>
<s9>patr.</s9>
</fA18>
<fA20><s1>2269-2272</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000133094560450</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>9 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0198137</s0>
</fA47>
<fA60><s1>P</s1>
<s2>C</s2>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We have investigated to develop novel vaccines against SARS CoV using cDNA constructs encoding the structural antigen; spike protein (S), membrane protein (M), envelope protein (E), or nucleocapsid (N) protein, derived from SARS CoV. Mice vaccinated with SARS-N or -M DNA using pcDNA 3.1(+) plasmid vector showed T cell immune responses (CTL induction and proliferation) against N or M protein, respectively. CTL responses were also detected to SARS DNA-transfected type II alveolar epithelial cells (T7 cell clone), which are thought to be initial target cells for SARS virus infection in human. To determine whether these DNA vaccines could induce T cell immune responses in humans as well as in mice, SCID-PBL/hu mice was immunized with these DNA vaccines. As expected, virus-specific CTL responses and T cell proliferation were induced from human T cells. SARS-N and SARS-M DNA vaccines and SCID-PBL/hu mouse model will be important in the development of protective vaccines.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Souris</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Mouse</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Ratón</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Vaccin génétique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Genetic vaccine</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Vaccina genética</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Grave</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Severe</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Grave</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Lymphocyte T</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>T-Lymphocyte</s0>
<s5>07</s5>
<s6>«T»-Lymphocyte</s6>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Linfocito T</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Cytotoxicité</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Cytotoxicity</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Citotoxicidad</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Immunodéficit mixte</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Combined immune deficiency</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Inmunodeficiencia mixta</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Mutation severe combined immunodeficiency (scid)</s0>
<s4>INC</s4>
<s5>79</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>13</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>13</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>13</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>16</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>16</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>16</s5>
</fC07>
<fN21><s1>121</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
<pR><fA30 i1="01" i2="1" l="ENG"><s1>World Congress on Vaccines and Immunisation</s1>
<s2>4</s2>
<s3>Tokyo JPN</s3>
<s4>2004-09-30</s4>
</fA30>
</pR>
</standard>
<server><NO>PASCAL 06-0198137 INIST</NO>
<ET>The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice</ET>
<AU>OKADA (Masaji); TAKEMOTO (Yuji); OKUNO (Yoshinobu); HASHIMOTO (Satomi); YOSHIDA (Shigeto); FUKUNAGA (Yukari); TANAKA (Takao); KITA (Yoko); KUWAYAMA (Sachiko); MURAKI (Yumiko); KANAMARU (Noriko); TAKAI (Hiroko); OKADA (Chika); SAKAGUCHI (Yayoi); FURUKAWA (Izumi); YAMADA (Kyoko); MATSUMOTO (Makoto); KASE (Tetsuo); DEMELLO (Daphne E.); PEIRIS (J. S. M.); CHEN (Pei-Jer); YAMAMOTO (Naoki); YOSHINAKA (Yoshiyuki); NOMURA (Tatsuji); ISHIDA (Isao); MORIKAWA (Shigeru); TASHIRO (Masato); SAKATANI (Mitsunori); KURSTAK (Edouard)</AU>
<AF>Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone/Sakai, Osaka 591-8555/Japon (1 aut., 2 aut., 4 aut., 6 aut., 7 aut., 8 aut., 9 aut., 10 aut., 11 aut., 12 aut., 13 aut., 14 aut., 15 aut., 16 aut., 28 aut.); Department of Infectious Diseases, Osaka Prefectural Institute of Public Health/3-69 Nakamichi 1-chome Higashinari-ku, Osaka 537-0025/Japon (3 aut., 18 aut.); Department of Infection and Immunity, Jichi Medical School, 3311-1 Yakushiji/Minamikawachi-machi, Tochigi 329-0498/Japon (5 aut.); Microbiological Research Institute, Otsuka Pharmaceutical Co., Ltd., 463-10, Kagasuno/Kawauchi-cho, Tokushima 771-019/Japon (17 aut.); Department of Pathology Cardinal Glennon Children's Hospital, St. Louis University Health Science Center, 1465 South Grand Blvd/St. Louis, MO 63104/Etats-Unis (19 aut.); Department of Microbiology, The University of Hong Kong, Pokfulam Road/Hong-Kong (20 aut.); Hepatitis Research Center, National Taiwan University College of Medicine, Room 328, 3F, No. 1, Sec. 1, Ren-ai Rd/Jhongjheng District 100, Taipei/Taïwan (21 aut.); Tokyo Medical and Dental University, 1-5-45 Yushima/Bunkyo-ku, Tokyo 113-8549/Japon (22 aut., 23 aut.); Central Institute for Experimental Animals, 1430 Nogawa, Miyamae/Kawasaki, Kanagawa 216-0001/Japon (24 aut.); Pharmaceutical Division, Kirin Brewery Co., 6-26-1 Jingumae/Shibuya, Tokyo 150-8011/Japon (25 aut.); National Institute of Infectious Diseases, 1-23-1 Toyama/Shinjuku-ku, Tokyo 162-8640/Japon (26 aut., 27 aut.); Infections Control World Organization, Faculty of Medicine, University of Montreal/Montreal, Que., H3C 3J7/Canada (1 aut.)</AF>
<DT>Publication en série; Congrès; Niveau analytique</DT>
<SO>Vaccine; ISSN 0264-410X; Coden VACCDE; Royaume-Uni; Da. 2005; Vol. 23; No. 17-18; Pp. 2269-2272; Bibl. 9 ref.</SO>
<LA>Anglais</LA>
<EA>We have investigated to develop novel vaccines against SARS CoV using cDNA constructs encoding the structural antigen; spike protein (S), membrane protein (M), envelope protein (E), or nucleocapsid (N) protein, derived from SARS CoV. Mice vaccinated with SARS-N or -M DNA using pcDNA 3.1(+) plasmid vector showed T cell immune responses (CTL induction and proliferation) against N or M protein, respectively. CTL responses were also detected to SARS DNA-transfected type II alveolar epithelial cells (T7 cell clone), which are thought to be initial target cells for SARS virus infection in human. To determine whether these DNA vaccines could induce T cell immune responses in humans as well as in mice, SCID-PBL/hu mice was immunized with these DNA vaccines. As expected, virus-specific CTL responses and T cell proliferation were induced from human T cells. SARS-N and SARS-M DNA vaccines and SCID-PBL/hu mouse model will be important in the development of protective vaccines.</EA>
<CC>002A05F04</CC>
<FD>Virus syndrome respiratoire aigu sévère; Souris; Homme; Vaccin génétique; Grave; Lymphocyte T; Cytotoxicité; Immunodéficit mixte; Syndrome respiratoire aigu sévère; Mutation severe combined immunodeficiency (scid)</FD>
<FG>Coronavirus; Coronaviridae; Nidovirales; Virus; Rodentia; Mammalia; Vertebrata; Appareil respiratoire pathologie; Virose; Infection; Poumon pathologie</FG>
<ED>Severe acute respiratory syndrome virus; Mouse; Human; Genetic vaccine; Severe; T-Lymphocyte; Cytotoxicity; Combined immune deficiency; Severe acute respiratory syndrome</ED>
<EG>Coronavirus; Coronaviridae; Nidovirales; Virus; Rodentia; Mammalia; Vertebrata; Respiratory disease; Viral disease; Infection; Lung disease</EG>
<SD>Severe acute respiratory syndrome virus; Ratón; Hombre; Vaccina genética; Grave; Linfocito T; Citotoxicidad; Inmunodeficiencia mixta; Síndrome respiratorio agudo severo</SD>
<LO>INIST-20289.354000133094560450</LO>
<ID>06-0198137</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000044 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000044 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    CovidV2
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0198137
   |texte=   The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice
}}

This area was generated with Dilib version V0.6.33.
Data generation: Sat Mar 28 17:51:24 2020. Site generation: Sun Jan 31 15:35:48 2021

	Serveur d'exploration Covid (26 mars)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Covid (26 mars)

The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice

The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri